Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3660857 | 1.00 | CYP2C9 (0.44) | CYP2C9ALDH1A1L3MBTL1TSHRTDP1 | |
| SCHEMBL9869703 | 0.88 | CYP2C9 (0.51) | CYP2C9ALDH1A1L3MBTL1TSHRTDP1 | |
| SCHEMBL2593542 | 0.88 | CYP2C9 (0.51) | CYP2C9ALDH1A1L3MBTL1TSHRTDP1 | |
| SCHEMBL2593541 | 0.88 | CYP2C9 (0.51) | CYP2C9ALDH1A1L3MBTL1TSHRTDP1 | |
| SCHEMBL15313611 | 0.88 | CYP2C9 (0.51) | CYP2C9ALDH1A1L3MBTL1TSHRTDP1 | |
| SCHEMBL30174225 | 0.85 | CYP2C9 (0.45) | CYP2C9ALDH1A1L3MBTL1TSHRTDP1 | |
| SCHEMBL25533356 | 0.85 | CYP2C9 (0.45) | CYP2C9ALDH1A1L3MBTL1TSHRTDP1 | |
| SCHEMBL4089002 | 0.82 | ALDH1A1 (0.38) | CYP2C9ALDH1A1L3MBTL1TSHRTDP1 | |
| SCHEMBL17091305 | 0.79 | CYP2C9 (0.49) | CYP2C9ALDH1A1L3MBTL1TSHRSMN1; SMN2 | |
| SCHEMBL17091307 | 0.79 | CYP2C9 (0.49) | CYP2C9ALDH1A1L3MBTL1TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2235001-B1 | PROCESS FOR PREPARING PYRIDINONE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8754230-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140012007-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-09 | — | — | US | disclosed |
| US-8558000-B2 | 4-pyridinone compounds and their use for cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-10-15 | — | — | US | disclosed |
| EP-2235001-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | Bristol-Myers Squibb Company (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009094427-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140012007-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | PAM, NQO1, PDXK | CYP2C9 72/4885ALDH1A1 88/4885L3MBTL1 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.